cetuximab

Known as: Cetuximab [Chemical/Ingredient], Anti-EGFR Monoclonal Antibody, Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
BACKGROUND Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?